Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$15,000.00
Feb 16, 2024
For-profit organization
Develop digital adoption plan
$15,000.00
Feb 16, 2024
For-profit organization
Develop digital adoption plan
$14,450.00
Feb 13, 2024
For-profit organization
Develop digital adoption plan
$450,000.00
Feb 1, 2024
For-profit organization
CIIP Korea - MTD-TPC - Music Therapy Devices for Mental Health: A Trans-Pacific Collaboration
1015298
LUCID, a Canadian digital health startup, and Emma Healthcare, a Korean SME specializing in advanced diagnostics, are collaborating to revolutionize neuropsychiatric care through the co-development of an AI-based music therapy solution. LUCID's BioMIR technology, which analyzes user data and predicts emotional and cognitive states to personalize digital music therapy, will be enhanced with Emma Healthcare's diagnostic capabilities and measurement expertise. This joint effort aims to optimize the effectiveness of the therapy offering by training it on diverse datasets from North American and Asian populations, ultimately providing personalized, clinically validated music therapy solutions for improved mental well-being worldwide.
$75,000.00
Jan 29, 2024
For-profit organization
Interactive bikes - bluetooth implementation
1015457
This technological innovation promises to enrich the cycling experience, opening up new possibilities in the fields of entertainment, education and therapy.
$14,849.73
Jan 8, 2024
For-profit organization
Develop digital adoption plan
$242,920.00
Jan 8, 2024
For-profit organization
Development of high protein chickpea (Cicer arietinum) variety using advanced plant breeding techniques.
1011864
AgGene has identified a set of candidate genes that can be disrupted and modulated to increase seed protein content through genome editing.
$20,000.00
Jan 7, 2024
For-profit organization
Gene Biotechnology Enterprises Ltd.-2023-2024-1015532
1015532
The purpose of this CanExport SMEs agreement is to support small- and medium-sized enterprises (SMEs) for activities related to export market development that are part of an export business case for a specific target market, particularly where activities are targeting departmental priority markets and sectors.
$448,853.00
Jan 1, 2024
Individual or sole proprietorship
Team Grant: E-Rare-3 Joint Transnational Call
174888
The goal of these studies is to collect and analyse comprehensive patient data to define targets for future therapies, taking into consideration innovation, safety, and efficacy.
$450,000.00
Jan 1, 2024
Individual or sole proprietorship
Team Grant: E-Rare-3 Joint Transnational Call
174890
The goal of these studies is to collect and analyse comprehensive patient data to define targets for future therapies, taking into consideration innovation, safety, and efficacy.